Search
for

    Glossary Bisphosphonates

    drugs that prevent bone density loss by inhibiting osteoclasts

    Bisphosphonates, also known as diphosphonates, are a class of drugs that prevent the loss of bone density. They are commonly prescribed to treat osteoporosis and similar bone diseases by inhibiting the activity of osteoclasts, the cells responsible for bone resorption. This helps to strengthen bones and reduce the risk of fractures.

    Research

    5 / 188 results

      research Dynamics of procollagen type 1 N-terminal propeptide in postmenopausal osteoporosis during bisphosphonate therapy and transcranial electrical stimulation

      May 2024 in “International journal of medicine and psychology.”
      In this study, combining transcranial electrical stimulation with bisphosphonate therapy in patients with postmenopausal osteoporosis resulted in a protective effect on bone collagen synthesis, as indicated by higher P1NP levels over 12 months, compared to bisphosphonates alone.

      research Gonadal dysgenesis and bone metabolism

      45 citations , February 2001 in “Joint bone spine”
      This study found that Turner’s syndrome is associated with significant bone mass decrease due to estrogen deficiency, which can be improved with estrogen therapy, while bone issues in Klinefelter’s syndrome may benefit from early androgen therapy and possibly bisphosphonates.

      research Ottawa, Ontario, Canada, February 13–16, 2013

      4 citations , June 2013 in “The Journal of Rheumatology”
      This abstract describes a program with various presentations and events focused on Canadian excellence in rheumatology but reports no new research findings.

      research Menopause

      3 citations , January 2007 in “Elsevier eBooks”
      The document concludes that individualized treatment and lifestyle changes are important for managing menopause symptoms and health risks.

    Learn

    — no results

    Community Join

    — no results